Vol 7, Supplement 6 (December 2018): Translational Andrology and Urology


Cholesterol pathway the Achilles heel in prostate cancer metastasis
Isabel Heidegger, Renate Pichler, Andreas Pircher
Nutritional implications for quality of life in bladder cancer survivors
Charles J. Rosser
T1G3 bladder cancer, bacillus Calmette-Guerin and radical cystectomy: continued debate
Andrew Brodie, Nadine McCauley, Jo Cresswell, Nikhil Vasdev
Will long term oncologic follow-up make the case for robotic assisted radical cystectomy?
Michael D. Gross, Bashir Al Hussein Al Awamlh, Jim C. Hu
Treating bladder adenocarcinoma
Georgios Tsironis, Aristotle Bamias
The association of BMI with risk of recurrence and progression in patients with non-muscle-invasive bladder cancer
Alina Vrieling
An immediate intravesical instillation of mitomycin C is of benefit in all prognostic risk groups with non-muscle-invasive bladder cancers
Willem Oosterlinck, Karel Decaestecker
Does obesity impact bladder cancer prognosis?—a long-lasting debate
Fabrizio Dal Moro, Michele Colicchia
A retrosigmoid ileal conduit might prevent ureteroileal anastomotic stricture after ileal conduit diversion
Cristiano Mendes Gomes, Luccas Soares Laferreira
Targeting splicing factors as molecular non-muscle invasive bladder cancer predictors
Kyoung-Hwa Lee, Ja Hyeon Ku
Immunonutrition in radical cystectomy: a novel approach to reduce postoperative complications?
Atiqullah Aziz, Oliver W. Hakenberg
Do we have all the facts to determine the impact of bacillus Calmette-Guérin therapy on bladder cancer?
Ratha Mahendran
Editorial comment: bladder preservation as a treatment strategy in muscle-invasive bladder cancer
Khaled Ajib, Girish S. Kulkarni
The patient’s perspective on blue light flexible cystoscopy: insight from a prospective clinical study
Nima Almassi, Eugene Pietzak
Redefining the role of immediate intravesical instillation of mitomycin C in non-muscle invasive bladder cancer
Deepak Batura
Sarcopenia is a reliable predictor of outcomes following radical cystectomy for bladder cancer
Matthew G. Kaag, Jay D. Raman
Is experience with extracorporeal urinary diversion following robotic assisted radical cystectomy necessary before transitioning to intracorporeal urinary diversion?
Wei Shen Tan, John D. Kelly
High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer
Renate Pichler, Wolfgang Loidl, Martin Pichler
Is it oncologically and clinically safe to adopt a bladder sparing approach in complete responders following neoadjuvant chemotherapy alone without proceeding to a radical cystectomy?
Ranjan Arianayagam, Anand Sharma, Nikhil Vasdev
Does robotic radical cystectomy impede oncological outcome in bladder cancer patients?
Günter Niegisch
Decreasing incidence of venous thromboembolic events after radical cystectomy: are we finally improving?
Benjamin T. Harper, Christopher J. D. Wallis, Zachary Klaassen
Is adjuvant chemotherapy better than neoadjuvant chemotherapy for those with node positive disease?
Joseph Zabell, Badrinath Konety
Biomarkers for the prediction of oncologic outcomes in nonmuscle invasive bladder cancer: state of affairs and new frontiers
Francesco Soria, Shahrokh F. Shariat
Challenging the dogma of simultaneous resection of bladder tumor and benign prostate
Matvey Tsivian, Alexander Tsivian
The timing of radical cystectomy following neoadjuvant chemotherapy
Venkat M. Ramakrishnan, Jairam R. Eswara
Impact of immunonutrition on radical cystectomy immunoresponse and outcomes; opportunity for peri-operative optimization
Marc A. Bjurlin, Angela B. Smith, William C. Huang
Frailty and sarcopenia impact surgical and oncologic outcomes after radical cystectomy in patients with bladder cancer
Ram Anil Pathak, Ashok K. Hemal